

NEW CHEMICAL ENTITIES

SMALL MOLECULES

| INN and/or CODE | PHARMACOLOGICAL CLASS | THERAPEUTIC INDICATIONS | DEVELOPMENT PHASE |
|-----------------------------|---|--|---|
| Dexloxiglumide (CR 2017) | CCK-1 receptor antagonist | <ul style="list-style-type: none"> Irritable Bowel Syndrome (IBS) Functional dyspepsia (FD) Gastro-Esophageal Reflux Disease (GERD) | <ul style="list-style-type: none"> Phase III |
| Andolast (CR 2039) | Airway specific anti-inflammatory agent with calcium-activated potassium channel modulator properties | <ul style="list-style-type: none"> Bronchial asthma Allergic rhinitis Chronic Obstructive Pulmonary Disease (COPD) | <ul style="list-style-type: none"> Phase III |
| Itriglumide (CR 2945) | CCK-2 receptor antagonist | <ul style="list-style-type: none"> Anxiety disorders Acid-related gastrointestinal disorders Gastrointestinal neoplasms | <ul style="list-style-type: none"> Phase II |
| Neboglamine (CR 2249) | Functional positive modulator of NMDA receptors with potent and selective inhibition of NE reuptake | <ul style="list-style-type: none"> Schizophrenia Drug abuse | <ul style="list-style-type: none"> Phase II |
| CR 3294 | Inhibitor of pro-inflammatory gene expression with potent ROS-generation preventing effect | <ul style="list-style-type: none"> Chemotherapy/Radiotherapy-Induced Mucositis Chemotherapy-Induced Diarrhea (CID) Inflammatory Bowel Diseases (IBD) | <ul style="list-style-type: none"> Phase II |
| CR 3465 | Leukotriene D ₄ receptor antagonist | <ul style="list-style-type: none"> Bronchial asthma Interstitial cystitis | <ul style="list-style-type: none"> Phase I |
| CR 4056 | Imidazoline I ₂ binding site ligand | <ul style="list-style-type: none"> Neuropathic pain Acute Nonspecific Pain | <ul style="list-style-type: none"> Preclinical Development |
| CR 5542 (series) | Orexin receptor antagonist | <ul style="list-style-type: none"> Anxiety disorders Compulsive disorders Insomnia and sleep disorders | <ul style="list-style-type: none"> Exploratory Development |
| CR 4892 (series) | NaV 1.8 blocker | <ul style="list-style-type: none"> Pain | <ul style="list-style-type: none"> Discovery |
| CR 5259 (series) | Aggrecanase inhibitor | <ul style="list-style-type: none"> Osteoarthritis: Disease Modifying Drug | <ul style="list-style-type: none"> Discovery |
| CR 5790 (series) | EP4 receptor antagonist | <ul style="list-style-type: none"> Osteoarthritis: Symptom Modifying Drug with potential Disease Modification properties | <ul style="list-style-type: none"> Discovery |
| CR 3663 (series) | Peripheral NMDA receptor antagonist | <ul style="list-style-type: none"> Osteoarthritis: Symptom Modifying Drug with potential Disease Modification properties | <ul style="list-style-type: none"> Discovery |
| CR 4174 (series) | COX-2 inhibitor NO donor (CINOD) | <ul style="list-style-type: none"> Osteoarthritis: Symptom Modifying Drug Inflammatory disorders | <ul style="list-style-type: none"> Discovery |

BIOLOGICS/THERAPEUTIC PROTEINS

| INN and/or CODE | PHARMACOLOGICAL CLASS | THERAPEUTIC INDICATIONS | DEVELOPMENT PHASE |
|--|-------------------------------------|---|---|
| CRB 0022 (monoclonal antibody) | Nerve Growth Factor (NGF) inhibitor | <ul style="list-style-type: none"> Osteoarthritis pain Chronic pain | <ul style="list-style-type: none"> Exploratory Development |
| CRB 0016 (monoclonal antibody) | Undisclosed | <ul style="list-style-type: none"> Osteoarthritis: Disease Modifying Drug | <ul style="list-style-type: none"> Exploratory Development |
| BRU 83-92 | HIV-1 protease inhibitor | <ul style="list-style-type: none"> AIDS | <ul style="list-style-type: none"> Exploratory Development |

R&D PIPELINE: LINE EXTENSIONS*

| INN and/or CODE | PHARMACOLOGICAL CLASS | THERAPEUTIC INDICATIONS | DEVELOPMENT PHASE |
|------------------|---|--|--|
| Silibinin | Inhibitor of hepatitis C virus (HCV) RNA polymerase | <ul style="list-style-type: none"> Hepatitis C (oral) HCV recurrence in liver transplantation (IV) | <ul style="list-style-type: none"> Phase I Phase III |

* Does not include portfolio management and new indications of marketed products